
Since TINRAD has made the aforementioned reagents indigenously, India’s dependence on foreign biotech companies will reduce significantly. Therefore prevent the drain of foreign reserves. The company is using local materials and manpower which will minimize the cost of introduced reagents and more importantly, generate employment. The previously told reagents will be provided to the masses with added value by using proprietary technology. They are cheaper and more stable than their imported alternatives that will enable the users to optimally utilize the resources and achieve greater results in the field.
TINRAD TEAM

Mrs. Manjula Shrivastav, B.Sc.
CEO, Partner

Dr. Tulsidas G. Shrivastav
M.Sc. (Clinical Biochemistry) Ph.D. (Immunodiagnostics) Chief scientist, partner

Mr. Manish Shrivastav
M.Sc. (Biochemistry) Ph.D. (Pursuing in Parasitology) Partner

Ms. Tripti Shrivastav.
BBA Partner

Dr. G. Lakshmi Kumari
M.Sc., Ph.D. Advisor Immunodiagnostic Expert

Dr. M. C. Kapilashrami
MBBS, MD Advisor Public Health Expert

Dr. Rita Singh
M.Sc., Ph.D. Advisor Immunodiagnostic and PCOD Expert

Dr. Anupam Basu
M.Sc., Ph.D. Advisor Immuno and Molecular Diagnostic Expert

Sh.Yashwant
CA, Lawyer

Mr. Sonu
Media Handler